At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRAY GRAYBUG VISION, INC.
Market Closed 03-20 16:00:00 EDT
5.50
+0.00
0.00%
High5.50
Low5.50
Vol0.00
Open5.50
D1 Closing5.50
Amplitude0.00%
Mkt Cap8.64M
Tradable Cap4.05M
Total Shares1.57M
T/O135.26K
T/O Rate0.00%
Tradable Shares737.07K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Calcimedica Reports Cash And Cash Equivalents Of About $34 Million As Graybug Vision Merger Close Expected To Support Operations Into H2 Of 2024
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.